Outrage: Legal Therapy Turned Trafficking

Matthew Perry’s final months reveal not just a tragic overdose story, but a blueprint for how America lets vulnerable patients slide from treatment room to drug market without ever leaving the doctor’s orbit.

Story Snapshot

A licensed physician admitted selling ketamine to Perry despite knowing his addiction history and lack of medical supervision.^[1]
Federal agents mapped a ketamine chain that ran from doctor to middleman to personal assistant, ending in Perry’s hot tub.^[2]
The government frames this as trafficking for profit, not a medical misstep, but the public record on the money is thinner than the headlines.^[1]^[2]
The case exposes a gray zone where real depression treatment and old-school drug dealing quietly blur together.

From therapy chair to trafficking chain

Matthew Perry did not start out buying ketamine from street dealers behind a strip mall. According to federal reporting and documentary accounts, his ketamine use began where many desperate patients’ journeys begin: in a clinic, under a doctor’s supervision, as a legal treatment for depression and anxiety.^[2]^[4] Ketamine, when used properly, can help people who do not respond to traditional antidepressants. That medical legitimacy gave cover to what came next, as treatment quietly slid into supply.

Federal prosecutors say one former California physician, Salvador Plasencia, crossed that line decisively. The United States Department of Justice states that Plasencia ran a Calabasas clinic and pleaded guilty to four counts of distribution of ketamine after repeatedly selling vials of the drug to Perry.^[1] Prosecutors emphasize that he did this despite knowing Perry’s long, public history of addiction and that ketamine was being administered not by trained staff, but by Perry’s personal assistant at home.^[1] That is not fringe gossip; it is the government’s official description in open court.

The “medical” supply line that bypassed medicine

The story did not stop with one doctor and one desperate patient. The Drug Enforcement Administration describes a broader ketamine pipeline built around Perry.^[2] Agents say dealer Jasveen Sangha worked with middleman Erik Fleming to move ketamine to Perry, eventually selling a staggering fifty-one vials into his circle.^[2] When investigators later raided Sangha, they reportedly found a money-counting machine, drug-packaging supplies, and thousands of dollars in cash—classic trafficking indicators that do not usually sit in the back office of a mental health clinic.^[2]

Those details matter for anyone who cares about personal responsibility and basic rule of law. The government does not treat this as a paperwork error in a busy practice; it brands Plasencia and Sangha as drug distributors.^[1]^[2] Plasencia surrendered his California medical license after pleading guilty.^[1] Sangha received a lengthy federal prison sentence.^[2] That is the system saying, in effect, “You stopped being a doctor and started being a dealer.” For conservatives who argue that professional credentials should not place anyone above the law, that framing aligns with common sense.

The elusive $55,000 and what we actually know

Documentary coverage now circulates a striking claim: that Perry paid roughly fifty-five thousand dollars in less than a month for ketamine, allegedly to “two doctors.” That number grabs attention because it sounds less like a medical bill and more like a cartel invoice. Yet the public record that federal authorities have released so far does not include bank statements, ledgers, or receipts proving that exact figure or how it split among providers.^[1]^[2]^[3] Without those documents, the fifty-five-thousand-dollar claim remains an allegation, not a proven fact.

What we do know from primary sources is more modest but still damning. Plasencia admitted in court that he sold ketamine vials, not just billed for clinic sessions.^[1] The Drug Enforcement Administration portrays cash-heavy transactions and dozens of vials changing hands through intermediaries.^[2] That picture supports a conclusion of unlawful distribution and reckless disregard for patient safety. It does not, by itself, document how much profit anyone pocketed or whether the prices exceeded typical, if expensive, off-label ketamine treatment. For those who prefer judgments grounded in evidence rather than outrage, that distinction matters.

Where treatment ends and personal responsibility begins

This case sits in a particularly uneasy space for people who believe both in individual accountability and in the need for honest medicine. Perry was not a minor. He was a wealthy, middle-aged man who openly battled addiction and, by all accounts, knew ketamine’s risks. Personal responsibility requires acknowledging that he chose to keep taking a powerful anesthetic, sometimes in a hot tub, even as his health deteriorated. That choice mattered, and no amount of anger at doctors fully erases it.^[2]

Matthew Perry paid doctors roughly $55,000 in less than a month for ketamine treatments. Investigators later uncovered worrisome text messages.

Watch “Hollywood Demons” Monday on ID and stream on @HBOMax.#HollywoodDemons pic.twitter.com/Wgv0bNbpFQ

— Investigation Discovery (@DiscoveryID) May 16, 2026

At the same time, federal filings show professionals who knew exactly what they were dealing with and sold the drug anyway.^[1]^[2] The Department of Justice says Plasencia understood Perry’s “well-documented history of drug addiction” and still kept supplying ketamine for unsupervised home use.^[1] The Drug Enforcement Administration notes that Sangha’s ketamine sales were linked not just to Perry’s death, but to an earlier overdose death in another customer.^[2] Those are not the actions of cautious physicians nudging a fragile patient through an experimental therapy; they look like merchants feeding demand.

What this means for the next vulnerable patient

The Perry case exposes a gap in how the country handles powerful drugs that straddle medicine and recreation. Ketamine can be a lifeline for some patients when used in a controlled clinic, with modest doses, clear documentation, and strict monitoring. It can also become a lucrative product for anyone willing to sell vials off the books to people who trust white coats more than street dealers. Once the line between those worlds blurs, addiction does not care which side the invoice came from.^[2]^[4]

For regulators and ordinary citizens, the lesson is uncomfortable but clear. Do not confuse “doctor-prescribed” with “safe,” and do not let moral panic replace facts. The record proves illegal distribution, reckless disregard for an addicted patient, and a supply chain that looked far more like trafficking than care.^[1]^[2] The record does not yet prove every dramatic dollar figure. If we want accountability that actually protects the next Matthew Perry, we must insist on both: hard evidence for every accusation, and zero tolerance when professionals cross the line from healer to dealer.